2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome

Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and...

Full description

Bibliographic Details
Main Authors: Yeon-Ji Kim, Han-Hae Kim, Chul-Soo Shin, Jong-Won Yoon, Seon-Min Jeon, Young-Ha Song, Kwang-Youn Kim, Kyungho Kim
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/15/8/1845
_version_ 1797604041790849024
author Yeon-Ji Kim
Han-Hae Kim
Chul-Soo Shin
Jong-Won Yoon
Seon-Min Jeon
Young-Ha Song
Kwang-Youn Kim
Kyungho Kim
author_facet Yeon-Ji Kim
Han-Hae Kim
Chul-Soo Shin
Jong-Won Yoon
Seon-Min Jeon
Young-Ha Song
Kwang-Youn Kim
Kyungho Kim
author_sort Yeon-Ji Kim
collection DOAJ
description Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity.
first_indexed 2024-03-11T04:40:34Z
format Article
id doaj.art-a2187367003645fca138a2f1619be442
institution Directory Open Access Journal
issn 2072-6643
language English
last_indexed 2024-03-11T04:40:34Z
publishDate 2023-04-01
publisher MDPI AG
record_format Article
series Nutrients
spelling doaj.art-a2187367003645fca138a2f1619be4422023-11-17T20:45:17ZengMDPI AGNutrients2072-66432023-04-01158184510.3390/nu150818452′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal MicrobiomeYeon-Ji Kim0Han-Hae Kim1Chul-Soo Shin2Jong-Won Yoon3Seon-Min Jeon4Young-Ha Song5Kwang-Youn Kim6Kyungho Kim7Korean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaUlcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity.https://www.mdpi.com/2072-6643/15/8/18452′-fucosyllactose3-fucosyllactoseinflammationtight junctionulcerative colitis
spellingShingle Yeon-Ji Kim
Han-Hae Kim
Chul-Soo Shin
Jong-Won Yoon
Seon-Min Jeon
Young-Ha Song
Kwang-Youn Kim
Kyungho Kim
2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
Nutrients
2′-fucosyllactose
3-fucosyllactose
inflammation
tight junction
ulcerative colitis
title 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_full 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_fullStr 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_full_unstemmed 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_short 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_sort 2 fucosyllactose and 3 fucosyllactose alleviates interleukin 6 induced barrier dysfunction and dextran sodium sulfate induced colitis by improving intestinal barrier function and modulating the intestinal microbiome
topic 2′-fucosyllactose
3-fucosyllactose
inflammation
tight junction
ulcerative colitis
url https://www.mdpi.com/2072-6643/15/8/1845
work_keys_str_mv AT yeonjikim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT hanhaekim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT chulsooshin 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT jongwonyoon 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT seonminjeon 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT younghasong 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT kwangyounkim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT kyunghokim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome